Therapeutic modulation of empathy: pharmacological, neurostimulation, and behavioral approaches

Empathy is a core neurobiological capacity that enables humans to perceive, understand, and respond to others' experiences, yet its deliberate modulation as a therapeutic target is still in its early stages of scientific development. This manuscript presents a hybrid narrative-scoping review synthesizing evidence across pharmacological, neurostimulation, and behavioral approaches aimed at enhancing or restoring empathic functioning. A structured literature search covering 2014-2025 was conducted across PubMed, PsycINFO, Web of Science, and Scopus, with emphasis on post-2020 research. Evidence was organized using an author-defined tiered synthesis framework, intended to support integrative interpretation rather than formal evidence grading. Across modalities, empathy can be modulated, but observed effect sizes are typically small to moderate, heterogeneous, and frequently transient. Pharmacological approaches such as intranasal oxytocin demonstrate modest, context-dependent effects (<i>d</i> = 0.24, 95% CI: 0.02-0.46), while MDMA-assisted therapy yields larger but highly context-restricted benefits (<i>d</i> ≈ 0.91) in trauma-focused psychotherapy and faces unresolved regulatory barriers. Neurostimulation techniques, including transcranial magnetic stimulation (<i>d</i> ≈ 0.18-0.20), provide causal insights into empathy-related circuits but show limited durability of behavioral effects. Behavioral interventions-particularly mindfulness-based programs (<i>d</i> = 0.37, 95% CI: 0.16-0.58 for programs >24 h) and compassion-focused programs-exhibit the greatest scalability and sustainability. Overall, empathy represents a scientifically promising yet clinically constrained therapeutic target. Reliable translation will require larger trials, standardized and ecologically valid outcome measures, and careful integration of neurobiological and psychosocial frameworks.